Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.65 |
| ▸ | FBP1 | P09467 | 2/20 | 0.63 |
| ▸ | VCP | P55072 | 1/20 | 0.63 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.51 |
| ▸ | MITF | O75030 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL100241 | 1.00 | NFE2L2 (0.65) | NFE2L2FBP1VCPCYP19A1MAPT | |
| SCHEMBL2062219 | 1.00 | NFE2L2 (0.65) | NFE2L2FBP1VCPCYP19A1MAPT | |
| SCHEMBL29453878 | 1.00 | NFE2L2 (0.65) | NFE2L2FBP1VCPCYP19A1MAPT | |
| Benzene SCHEMBL28683414 | 0.98 | NFE2L2 (0.68) | NFE2L2FBP1VCPCYP19A1MAPT | |
| SCHEMBL1819754 | 0.85 | NFE2L2 (0.67) | NFE2L2FBP1VCPCYP19A1MAPT | |
| SCHEMBL5804307 | 0.85 | NFE2L2 (0.67) | NFE2L2FBP1VCPCYP19A1MAPT | |
| SCHEMBL15498134 | 0.84 | NFE2L2 (0.89) | NFE2L2FBP1VCPCYP19A1MAPT | |
| SCHEMBL11301074 | 0.80 | CYP19A1 (0.93) | NFE2L2FBP1VCPCYP19A1MAPT | |
| SCHEMBL11301072 | 0.80 | CYP19A1 (0.93) | NFE2L2FBP1VCPCYP19A1MAPT | |
| SCHEMBL3130064 | 0.79 | APP (0.60) | FBP1CYP19A1MAPTALDH1A1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114039042-B | Silicon oxide negative electrode material with artificial SEI film, and preparation method and application thereof | 惠州亿纬锂能股份有限公司 | 2023-07-28 | — | — | CN | claimed |
| CN-114039042-A | Silicon monoxide negative electrode material with artificial SEI film and preparation method and application thereof | 惠州亿纬锂能股份有限公司 | 2022-02-11 | — | — | CN | claimed |
| EP-3838903-B1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR | INCYTE HOLDINGS CORP (US) | 2023-11-22 | — | — | EP | disclosed |
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2023-09-05 | — | — | US | disclosed |
| CN-114039042-B | Silicon oxide negative electrode material with artificial SEI film, and preparation method and application thereof | 惠州亿纬锂能股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-114039042-B | Silicon oxide negative electrode material with artificial SEI film, and preparation method and application thereof | 惠州亿纬锂能股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| US-20220395506-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2022-12-15 | — | — | US | disclosed |
| US-11331320-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2022-05-17 | — | — | US | disclosed |
| CN-114039042-A | Silicon monoxide negative electrode material with artificial SEI film and preparation method and application thereof | 惠州亿纬锂能股份有限公司 | 2022-02-11 | — | — | CN | disclosed |
| CN-114039042-A | Silicon monoxide negative electrode material with artificial SEI film and preparation method and application thereof | 惠州亿纬锂能股份有限公司 | 2022-02-11 | — | — | CN | disclosed |
| EP-3838903-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR | Incyte Holdings Corporation (US) | 2021-06-23 | — | — | EP | disclosed |
| US-6426345-B1 | PHOSPHODIESTERASE INHIBITORS; ANTIINFLAMMATORY AGENTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-07-30 | — | — | US | disclosed |
| US-20020025965-A1 | Antiserotonine agents | ADIR ET COMPAGNIE (FR) | 2002-02-28 | — | — | US | disclosed |
| EP-1170288-A2 | Diphenylureum derivatives and their use as alpha2/5-HT2c antagonists | LES LABORATOIRES SERVIER (FR) | 2002-01-09 | — | — | EP | disclosed |
| EP-0920867-A1 | Pyrido[2,3-a]pyrazine derivatives as PDE-IV and TNF inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-06-09 | — | — | EP | disclosed |
| US-4137412-A | REACTING HALOGENO-AZAALKENE WITH ALPHA, BETA-UNSATURATED NITRILE | BAYER AKTIENGESELLSCHAFT (DE) | 1979-01-30 | — | — | US | disclosed |
| US-4051177-A | PROCESS FOR THE PREPARATION OF UNSATURATED AMINO COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DT) | 1977-09-27 | — | — | US | disclosed |
| US-4010151-A | Water insoluble mono azo and disazo dyes containing cinnamonitrile group | PRODUITS CHIMIQUES UGINE KUHLMANN (FR) | 1977-03-01 | — | — | US | disclosed |
| US-4008213-A | WATER INSOLUBLE | UGINE KUHLMANN (FR) | 1977-02-15 | — | — | US | disclosed |
| US-4002673-A | GROUP VIII METAL SULFIDE AS HYDROGENATION CATALYST | BAYER AKTIENGESELLSCHAFT (DT) | 1977-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220395506-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | NFE2L2 2032/4885FBP1 2517/4885VCP 4376/4885 |
| US-20020025965-A1 | Antiserotonine agents | HTR2C, HTR3C, HTR3A | NFE2L2 1426/4885FBP1 4712/4885VCP 4743/4885 |
| US-11744832-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | JAK3, JAK1, JAK2 | NFE2L2 2032/4885FBP1 2517/4885VCP 4376/4885 |
| US-11331320-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | JAK3, JAK1, JAK2 | NFE2L2 2032/4885FBP1 2517/4885VCP 4376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.